The trajectory of companies tied to Sildenafil's legacy presents a challenging investment landscape. While the initial surge generated substantial profits , generic alternatives have significantly diminished sales . Investing in associated pharmaceutical firms now requires a thorough assessment of patent protection , evolving healthcare shifts , an